Stony Brook (N.Y.) Heart Institute became the first center globally to administer a commercial dose of plozasiran, a newly approved RNA-interference therapy for familial chylomicronemia syndrome.
The Center for Advanced Lipid Management delivered the therapy within days of FDA approval, according to a Dec. 30 news release.
Plozasiran targets apolipoprotein C-III and, in phase 3 trials, significantly reduced triglyceride levels and pancreatitis episodes in patients with familial chylomicronemia syndrome, a rare genetic disorder that prevents the body from properly breaking down dietary fats. The syndrome affects an estimated 6,500 people in the U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
